Charles River Laboratories International (NYSE:CRL) Hits New 12-Month High – What’s Next?

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $359.89 and last traded at $354.94, with a volume of 77,128 shares changing hands. The stock had previously closed at $357.27.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Robert W. Baird raised their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Mizuho boosted their price objective on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, UBS Group assumed coverage on Charles River Laboratories International in a report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $302.33.

Charles River Laboratories International Price Performance

The business has a fifty day moving average of $299.04 and a 200-day moving average of $220.87. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market capitalization of $17.86 billion, a P/E ratio of -77.15, a price-to-earnings-growth ratio of 3.23 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the transaction, the executive vice president directly owned 4,807 shares of the company’s stock, valued at $1,655,578.87. The trade was a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 118,169 shares of company stock valued at $35,191,216 over the last ninety days. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International

A number of institutional investors and hedge funds have recently modified their holdings of CRL. Dimensional Fund Advisors LP increased its stake in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares during the last quarter. Amundi grew its stake in Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after purchasing an additional 492,301 shares during the period. Van Berkom & Associates Inc. grew its position in shares of Charles River Laboratories International by 11.2% during the 1st quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after acquiring an additional 50,462 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Charles River Laboratories International by 2.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock valued at $51,099,000 after buying an additional 6,401 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.